From the Journals

Second-melanoma risk higher with indoor tanning


 

FROM THE JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Patients who use indoor tanning beds are more likely to develop a second primary melanoma, and do it more quickly, than those who avoid indoor tanning, according to a retrospective study involving 434 melanoma patients.

Incidence and timing of second primary melanomas
Over the course of the study, 88 patients developed multiple primary melanomas. In the year after the original diagnosis, 56% of the patients exposed to artificial UV radiation (UVR) were diagnosed with a second primary melanoma versus 18% of the nonexposed subjects, Yang Li of Washington University, St. Louis, and her associates said in the Journal of the American Academy of Dermatology.

The incidence of second melanomas over the entire 16-year course of the study was 25.2% among the tanning-bed users and 18.6% for nonusers. Among these study subjects – 27 with tanning-bed exposure and 61 without – median time to the second tumor was 225 days (0.62 years) for exposed patients and 1,280 days (3.50 years) for those with no exposure, the investigators reported.

This study, they wrote, is the first to show that “patients who had second primary melanoma diagnoses were more likely to have had” exposure to artificial UVR. The increased radiation intensity of tanning beds, “as opposed to UVR from ambient sunlight, in a physiologically vulnerable patient population [fair-skinned persons] at an early age contributes to our findings of decreased tumor lag time.”

SOURCE: Li Y et al. J Am Acad Dermatol. 2018;79(6):1101-8.

Recommended Reading

Uveal melanoma: NCCN provides first pathway-based guidelines
MDedge Dermatology
Vemurafenib-Induced Plantar Hyperkeratosis
MDedge Dermatology
Re-excision unnecessary in moderately dysplastic nevi with positive margins
MDedge Dermatology
Checkpoint inhibitor linked to antiphospholipid syndrome in melanoma patient
MDedge Dermatology
Mobile App Rankings in Dermatology
MDedge Dermatology
Xanthogranulomatous Reaction to Trametinib for Metastatic Malignant Melanoma
MDedge Dermatology
Cross-contamination of Pathology Specimens: A Cautionary Tale
MDedge Dermatology
Checkpoint inhibitor doubles 3-year survival rate of BRAF wild-type advanced melanoma
MDedge Dermatology
Nivo + ipi shows durable activity against metastatic melanoma
MDedge Dermatology
New pregnancy, genetic testing guidance added to AAD’s melanoma guidelines
MDedge Dermatology